Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
38.63
-0.27 (-0.69%)
Dec 20, 2024, 4:00 PM EST - Market closed
Xenon Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
259
Market Cap
2.95B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BrightSpring Health Services | 10.59B |
QuidelOrtho | 2.82B |
Envista Holdings | 2.50B |
Warby Parker | 742.53M |
Amicus Therapeutics | 493.67M |
Veracyte | 425.33M |
Merus | 35.93M |
Janux Therapeutics | 13.05M |
XENE News
- 15 days ago - Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024 - GlobeNewsWire
- 26 days ago - Xenon to Showcase New Long-Term Azetukalner Data at AES 2024 - GlobeNewsWire
- 5 weeks ago - Xenon to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Xenon Pharmaceuticals Inc. (XENE) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Xenon Reports Q3 2024 Financial Results and Business Update - GlobeNewsWire
- 6 weeks ago - Xenon to Report Q3 2024 Financial Results on November 12, 2024 - GlobeNewsWire
- 2 months ago - Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference - GlobeNewsWire
- 3 months ago - Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress - GlobeNewsWire